ERBB2 and ovarian carcinoma: To assess iMSCEndostatin’s recognition capability for Her2 (+) tumors, two co-culture systems were established: BT474 (human breast cancer)—iMSCEndostatin and Skov3 (human ovarian cancer)—iMSCEndostatin.